Vivus re-submits Qnexa to the FDA for Obesity treatment

Vivus has resubmitted its new drug application to the FDA for its obesity treatment Qnexa (phentermine/topiramate), for a narrower patient population, which would include overweight men and women of non-childbearing potential. Vivus expects a final FDA decision in the second quarter of 2012. The question of potential birth defects associated with topiramate is being met with a new trial called FORTRESS and the proposal to exclude child-bearing women from the indication.